A novel tumor necrosis factor-α inhibitory protein, TIP-B1

被引:14
作者
Berleth, ES [1 ]
Henn, AD [1 ]
Gurtoo, HL [1 ]
Wollman, R [1 ]
Alderfer, JL [1 ]
Mihich, E [1 ]
Ehrke, MJ [1 ]
机构
[1] Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 2000年 / 22卷 / 12期
关键词
mammary; fibroblasts; cytotoxicity; apoptosis; TNF;
D O I
10.1016/S0192-0561(00)00071-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
TIP-B1, a novel TNF inhibitory protein, has been identified, purified and characterized from cytosolic extracts of TNF-treated human fibroblasts, and a partial TIP-B1 cDNA clone has been obtained. The (27 kDa pI approximate to 4.5 TIP-B1 protein is unique based on both the sequence of three internal peptides (comprising 51 amino acids), and the nucleotide sequence of the corresponding cDNA clone. TNF-sensitive cells, when exposed to TIP-B1 prior to the addition of TNF, are completely protected from TNF-induced lysis. Thus, this TIP-B1 treatment effectively makes these cells TNF-resistant. Furthermore, TIP-B1 protects cells from apoptotic lysis induced by TNF. TIP-BI does not interfere with the interactions between TNF and the TNF receptors based on flow cytometric analysis of the cellular binding of biotinylated TNF. These and other data indicate that TIP-B1 is not a soluble TNF receptor, nor an anti-TNF antibody, nor a protease that degrades TNF, yet TIP-B1 functions when added exogenously to cells. Thus, TIP-B1 is not one of the proteins previously reported to be involved in resistance to TNF. The fact that incubation of the newly discovered novel TIP-B1 with TNF-sensitive cells protects them from TNF-induced cell death, including TNF-mediated apoptosis, makes TIP-B1 a candidate for therapeutic modulation of TNF-induced effects. (C) 2000 International Society for Immunopharmacology. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1137 / 1142
页数:6
相关论文
共 24 条
  • [1] Berleth ES, 1999, CANCER RES, V59, P5497
  • [2] BOSS JM, 1991, IMMUNOLOGY, V73, P309
  • [3] EHRKE M, 1986, 14TH INT CANC C BUD, V3, P916
  • [4] Doxorubicin plus tumor necrosis factor α combination treatments in EL4-lymphoma-bearing C57BL/6 mice
    Ehrke, MJ
    Verstovsek, S
    Ujházy, P
    Meer, JM
    Eppolito, C
    Maccubbin, DL
    Mihich, E
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 45 (06) : 287 - 298
  • [5] EHRKE MJ, 1988, CANCER IMMUNOL IMMUN, V27, P103
  • [6] Ehrke MJ, 2000, INT J CANCER, V87, P101, DOI 10.1002/1097-0215(20000701)87:1<101::AID-IJC15>3.0.CO
  • [7] 2-B
  • [8] CYCLOPHOSPHAMIDE PLUS TUMOR-NECROSIS-FACTOR-ALPHA CHEMOIMMUNOTHERAPY CURED MICE - LIFELONG IMMUNITY AND REJECTION OF RE-IMPLANTED PRIMARY LYMPHOMA
    EHRKE, MJ
    VERSTOVSEK, S
    KRAWCZYK, CM
    UJHAZY, P
    ZALESKIS, G
    MACCUBBIN, DL
    MIHICH, E
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (03) : 463 - 471
  • [9] HENN AD, 2000, UNPUB FASEB J
  • [10] HORI K, 1987, CANCER RES, V47, P2793